Effect of exposure to interleukin-21 at various time points on human natural killer cell culture

Cytotherapy

Volumn 16, Issue 10, 2014, Pages 1419-1430

  Lim, Dong Pyo ^a   Jang, Youn Young ^b   Kim, Seokho ^c   Koh, Sang Seok ^c   Lee, Je Jung ^b   Kim, Ju Sun ^d   Thi Phan, Minh Trang ^a,b   Shin, Dong Jun ^b,d   Shin, Myung Geun ^a   Lee, Seung Hwan ^e   Yoon, Meesun ^a   Kim, Sang Ki ^d   Yoon, Jung Han ^a   Park, Min Ho ^a   Cho, Duck ^a,b  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Kongju National University   (South Korea)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

IL 15; IL 2; IL 21; Natural killer cells

Indexed keywords

GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 15; INTERLEUKIN 21; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL KILLER CELL RECEPTOR; PERFORIN; INTERLEUKIN 2; INTERLEUKIN DERIVATIVE;

ARTICLE; CELL DEATH; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NK CELL CULTURE; PROTEIN EXPRESSION; TELOMERE HOMEOSTASIS; ADULT; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; K562 CELL LINE; METABOLISM; NATURAL KILLER CELL; TIME;

ADULT; CELL PROLIFERATION; CELLS, CULTURED; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKINS; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; PERFORIN; TELOMERE HOMEOSTASIS; TIME FACTORS;

EID: 84908546580     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.04.008     Document Type: Article

References (29)

1. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
2. Whiteside T.L., Sung M.W., Nagashima S., Chikamatsu K., Okada K., Vujanovic N.L. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo. Clin Cancer Res 1998, 4:1135-1145.
3. Spolski R., Leonard W.J. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008, 26:57-79.
4. Wang K.S., Frank D.A., Ritz J. Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood 2000, 95:3183-3190.
5. Henney C.S., Kuribayashi K., Kern D.E., Gillis S. Interleukin-2 augments natural killer cell activity. Nature 1981, 291:335-338.
6. Carson W.E., Giri J.G., Lindemann M.J., Linett M.L., Ahdieh M., Paxton R., et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. JExp Med 1994, 180:1395-1403.
7. Salagianni M., Baxevanis C.N., Papamichail M., Perez S.A. New insights into the role of NK cells in cancer immunotherapy. Oncoimmunology 2012, 1:205-207.
8. Parkhurst M.R., Riley J.P., Dudley M.E., Rosenberg S.A. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011, 17:6287-6297.
9. Salagianni M., Lekka E., Moustaki A., Iliopoulou E.G., Baxevanis C.N., Papamichail M., et al. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. JImmunol 2011, 186:3327-3335.
10. Sutlu T., Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. JIntern Med 2009, 266:154-181.
11. Cho D., Campana D. Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med 2009, 29:89-96.
12. Imai C., Iwamoto S., Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005, 106:376-383.
13. Harada H., Saijo K., Watanabe S., Tsuboi K., Nose T., Ishiwata I., et al. Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT. Jpn J Cancer Res 2002, 93:313-319.
14. Denman C.J., Senyukov V.V., Somanchi S.S., Phatarpekar P.V., Kopp L.M., Johnson J.L. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 2012, 7:e30264.
15. Park Y.K., Shin D.J., Cho D., Kim S.K., Lee J.J., Shin M.G., et al. Interleukin-21 increases direct cytotoxicity and IFN-gamma production of ex vivo expanded NK cells towards breast cancer cells. Anticancer Res 2012, 32:839-846.
16. Brady J., Carotta S., Thong R.P., Chan C.J., Hayakawa Y., Smyth M.J., et al. The interactions of multiple cytokines control NK cell maturation. JImmunol 2010, 185:6679-6688.
17. Strbo N., de Armas L., Liu H., Kolber M.A., Lichtenheld M., Pahwa S. IL-21 augments natural killer effector functions in chronically HIV-infected individuals. AIDS 2008, 22:1551-1560.
18. Fujisaki H., Kakuda H., Shimasaki N., Imai C., Ma J., Lockey T., et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009, 69:4010-4017.
19. Lim S.A., Kim T.J., Lee J.E., Sonn C.H., Kim K., Kim J., et al. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. Cancer Res 2013, 73:2598-2607.
20. Jang Y.Y., Cho D., Kim S.K., Shin D.J., Park M.H., Lee J.J., et al. An improved flow cytometry-based natural killer cytotoxicity assay involving calcein AM staining of effector cells. Ann Clin Lab Sci 2012, 42:42-49.
21. Coquet J.M., Kyparissoudis K., Pellicci D.G., Besra G., Berzins S.P., Smyth M.J., et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. JImmunol 2007, 178:2827-2834.
22. Sondergaard H., Skak K. IL-21: roles in immunopathology and cancer therapy. Tissue Antigens 2009, 74:467-479.
23. Perez S.A., Mahaira L.G., Sotiropoulou P.A., Gritzapis A.D., Iliopoulou E.G., Niarchos D.K., et al. Effect of IL-21 on NK cells derived from different umbilical cord blood populations. Int Immunol 2006, 18:49-58.
24. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57-63.
25. Parrish-Novak J., Foster D.C., Holly R.D., Clegg C.H. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. JLeukoc Biol 2002, 72:856-863.
26. de Rham C., Ferrari-Lacraz S., Jendly S., Schneiter G., Dayer J.M., Villard J., et al. The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res Ther 2007, 9:R125.
27. Konnikova L., Simeone M.C., Kruger M.M., Kotecki M., Cochran B.H. Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res 2005, 65:6516-6520.
28. Brady J., Hayakawa Y., Smyth M.J., Nutt S.L. IL-21 induces the functional maturation of murine NK cells. JImmunol 2004, 172:2048-2058.
29. Baek H.J., Kim J.S., Yoon M., Lee J.J., Shin M.G., Ryang D.W., et al. Ex vivo expansion of natural killer cells using cryopreserved irradiated feeder cells. Anticancer Res 2013, 33:2011-2019.